日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Imlunestrant 是一种口服、脑渗透性选择性雌激素受体降解剂，对 ESR1 野生型和突变型乳腺癌具有强效抗肿瘤活性

期刊:Cancer Research
影响因子:12.5
doi:10.1158/0008-5472.CAN-24-2608
Shripad V Bhagwat #, Cecilia Mur #, Matthew Vandekopple #, Baohui Zhao, Weihua Shen, Carlos Marugán, Andrew Capen, Lisa Kindler, Jennifer R Stephens, Lysiane Huber, Mark A Castanares, David Garcia-Tapia, Jeff D Cohen, Jolie Bastian, Brian Mattioni, Eunice Yuen, Thomas K Baker, Vivian Rodriguez Cruz,
肿瘤
乳腺癌
发表日期：2025
文献求助 收藏

Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Aurora A 选择性抑制剂 LY3295668 可导致癌细胞显性有丝分裂停滞、凋亡，并显示出强大的临床前抗肿瘤功效

期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-18-0529
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Carlos Marugán, Karsten Boehnke, Carmen Baquero, Yu-Hua Hui, Sonya C Chapman, Yanzhu Yang, Yi Zeng, Sarah M Bogner, Robert T Foreman, Andrew Capen, Gregory P Donoho, Robert D Van Horn, Darlene S Barnard, Jack A Dempsey, Richard P Beckmann, 
信号转导
肿瘤
肿瘤细胞
Apoptosis
发表日期：2019
文献求助 收藏

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

CDK4/6 抑制剂 Abemaciclib 可诱导 T 细胞炎症肿瘤微环境并增强 PD-L1 检查点阻断的疗效

期刊:Cell Reports
影响因子:7.5
doi:10.1016/j.celrep.2018.02.053
David A Schaer, Richard P Beckmann, Jack A Dempsey, Lysiane Huber, Amelie Forest, Nelusha Amaladas, Yanxia Li, Ying Cindy Wang, Erik R Rasmussen, Darin Chin, Andrew Capen, Carmine Carpenito, Kirk A Staschke, Linda A Chung, Lacey M Litchfield, Farhana F Merzoug, Xueqian Gong, Philip W Iversen, Sean B
信号转导
肿瘤
T细胞
Checkpoint
发表日期：2018
文献求助 收藏

Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3

激活Wnt/β-Catenin通路治疗黑色素瘤——新型糖原合酶激酶3选择性抑制剂LY2090314的应用

期刊:PLoS One
影响因子:2.9
doi:10.1371/journal.pone.0125028
Jennifer M Atkinson, Kenneth B Rank, Yi Zeng, Andrew Capen, Vipin Yadav, Jason R Manro, Thomas A Engler, Marcio Chedid
信号转导
肿瘤
黑色素瘤
WB
Wnt/β-Catenin
发表日期：2015
文献求助 收藏